- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04198766
Estudio de INBRX-106 e INBRX-106 en combinación con pembrolizumab en sujetos con tumores sólidos localmente avanzados o metastásicos (agonista hexavalente de OX40)
Un estudio abierto, multicéntrico, primero en humanos, de aumento de dosis, de fase 1 de INBRX-106 e INBRX-106 en combinación con pembrolizumab en sujetos con tumores sólidos metastásicos o localmente avanzados
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Droga: INBRX-106 - Hexavalent OX40 agonist antibody
- Droga: pembrolizumab 200 mg
- Droga: pembrolizumab 400 mg
- Droga: Carboplatin AUC-5
- Droga: Pemetrexed 500 mg/m2
- Droga: Cisplatin 75mg/m2
- Droga: Carboplatin AUC-6
- Droga: Paclitaxel 200mg/m2
- Droga: Nab paclitaxel 100mg/m2
- Droga: Gemcitabine (1000 mg/m2)
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Director - Inhibrx Biosciences, Inc
- Número de teléfono: 858-500-7833
- Correo electrónico: clinicaltrials@inhibrx.com
Ubicaciones de estudio
-
-
-
Busan, Corea del Sur
- Aún no reclutando
- Inje University College of Medicine
-
Investigador principal:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Corea del Sur
- Aún no reclutando
- Chungbuk National University Hospital
-
Investigador principal:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Corea del Sur
- Reclutamiento
- The Catholic University of Korea, St. Vincent's Hospital
-
Investigador principal:
- Byoung Yong Shim
-
Hwasun, Corea del Sur
- Aún no reclutando
- Chonnam National University Hwasun Hospital
-
Investigador principal:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Corea del Sur
- Aún no reclutando
- Gachon University Gil Medical Center
-
Investigador principal:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Corea del Sur
- Aún no reclutando
- CHA Bundang Medical Center
-
Investigador principal:
- Yoon Beom Sang
-
Seoul, Corea del Sur
- Reclutamiento
- Asan Medical Center
-
Contacto:
- Bokyeong Jung, RN
- Correo electrónico: bokyeong_jung@amc.seoul.kr
-
Investigador principal:
- Dae Ho Lee, MD
-
Seoul, Corea del Sur
- Reclutamiento
- Severance Hospital, Yonsei University Health System
-
Contacto:
- Miyeon Lee
- Correo electrónico: lee_my@yuhs.ac
-
Investigador principal:
- Sun Mun Lim
-
Seoul, Corea del Sur
- Reclutamiento
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Investigador principal:
- SookHee Hong
-
Contacto:
- Na Ayn
- Correo electrónico: Ahnna331@gmail.com
-
Seoul, Corea del Sur
- Aún no reclutando
- Korea University Anam Hospital
-
Investigador principal:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Corea del Sur
- Aún no reclutando
- Hanyang University Seoul Hospital
-
Investigador principal:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Corea del Sur
- Aún no reclutando
- Korea University Guro Hospital
-
Investigador principal:
- Sung Yong Lee
-
Investigador principal:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Corea del Sur
- Aún no reclutando
- Ajou University Hospital
-
Investigador principal:
- Yong-Won Choi, MD
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Activo, no reclutando
- City of Hope
-
Glendale, California, Estados Unidos, 91204
- Reclutamiento
- Oncura Health
-
Contacto:
- Elizabeth Brown
- Correo electrónico: Elizabeth.Brown@lahomg.com
-
Investigador principal:
- Sungwon Kyung, MD
-
La Jolla, California, Estados Unidos, 92037
- Aún no reclutando
- UC San Diego Health - Moores Cancer Center
-
Investigador principal:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Estados Unidos, 90027
- Reclutamiento
- California Research Institute
-
Investigador principal:
- Ghassan Al-Jazayrly, MD
-
Contacto:
- Swati Shrestha
- Correo electrónico: sw@caresinst.com
-
Los Angeles, California, Estados Unidos, 90069
- Reclutamiento
- Valkyrie Clinical Trials
-
Investigador principal:
- David Berz, MD
-
Contacto:
- Myo Zaw
- Correo electrónico: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Estados Unidos, 90033
- Aún no reclutando
- University of Southern California Norris Comprehensive Cancer Center
-
Investigador principal:
- Jorge Nieva, MD
-
Murrieta, California, Estados Unidos, 92562
- Reclutamiento
- Valkyrie Clinical Trials
-
Investigador principal:
- David Berz, MD
-
Contacto:
- Isabella Gudino
- Correo electrónico: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Estados Unidos, 95403
- Reclutamiento
- Providence Medical Foundation
-
Investigador principal:
- Ian Anderson, MD
-
Contacto:
- Clinical Research Coordinator
- Número de teléfono: 1181 707-521-3810
- Correo electrónico: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Estados Unidos, 80228
- Aún no reclutando
- Valkyrie Clinical Trials - Colorado
-
Investigador principal:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Reclutamiento
- Clermont Oncology Center
-
Investigador principal:
- Gopal Kunta, MD
-
Contacto:
- Kiran Penta
- Correo electrónico: kiran@aorcorp.com
-
Orange City, Florida, Estados Unidos, 32763
- Reclutamiento
- Mid Florida Hematology and Oncology Center
-
Investigador principal:
- Santosh Nair, MD
-
Contacto:
- Kiran Penta
- Correo electrónico: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Activo, no reclutando
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Aún no reclutando
- University of Illinois Cancer Center
-
Investigador principal:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Estados Unidos, 60637
- Activo, no reclutando
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa
-
Investigador principal:
- Douglas Laux, MD
-
Contacto:
- Jordan Harrelson
- Número de teléfono: 319-467-5831
- Correo electrónico: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Reclutamiento
- Norton Cancer Institute
-
Investigador principal:
- John Hamm, MD
-
Contacto:
- Jenn Broadway, RN
- Número de teléfono: 19535 502-629-2500
- Correo electrónico: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Reclutamiento
- Henry Ford Cancer Institute
-
Investigador principal:
- Amy Weise, MD
-
Contacto:
- Mahmoud Hossami
- Número de teléfono: 313-725-7842
- Correo electrónico: mhossam1@hfhs.org
-
Detroit, Michigan, Estados Unidos, 48201
- Terminado
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Activo, no reclutando
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Estados Unidos, 55426
- Activo, no reclutando
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Terminado
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Aún no reclutando
- Washington University in St. Louis School of Medicine
-
Investigador principal:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- Terminado
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Aún no reclutando
- Nebraska Cancer Specialists - Grand Island
-
Investigador principal:
- Ralph Hauke, MD
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Nebraska Cancer Specialists
-
Investigador principal:
- Ralph Hauke, MD
-
Contacto:
- Lindsey Becker
- Número de teléfono: 402-691-5255
- Correo electrónico: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Aún no reclutando
- MD Anderson Cancer Center at Cooper
-
Investigador principal:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Activo, no reclutando
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Activo, no reclutando
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Activo, no reclutando
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Aún no reclutando
- Lehigh Valley Health Network
-
Investigador principal:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37923
- Aún no reclutando
- University of Tennessee Health Science Center
-
Investigador principal:
- Sean Jordan, MD
-
Nashville, Tennessee, Estados Unidos, 37204
- Activo, no reclutando
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Terminado
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Estados Unidos, 79915
- Terminado
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Estados Unidos, 78229
- Terminado
- NEXT Oncology
-
The Woodlands, Texas, Estados Unidos, 77380
- Terminado
- Renovatio Clinical
-
Tyler, Texas, Estados Unidos, 75701
- Reclutamiento
- The University of Texas Health Science Center at Tyler
-
Contacto:
- Chaney Story
- Correo electrónico: Chaney.Story@uttyler.edu
-
Investigador principal:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Terminado
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Froedtert Hospital and the Medical College of Wisconsin
-
Investigador principal:
- Jonathan Thompson, MD
-
Contacto:
- Ellen Smith
- Correo electrónico: eksmith@mcw.edu
-
-
-
-
-
Singapore, Singapur
- Terminado
- Curie Oncology
-
Singapore, Singapur
- Terminado
- Icon Cancer Centre Farrer Park
-
Singapore, Singapur
- Terminado
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Changhua, Taiwán
- Activo, no reclutando
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwán
- Activo, no reclutando
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwán
- Activo, no reclutando
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwán
- Activo, no reclutando
- National Cheng Kung University Hospital
-
Taipei, Taiwán
- Terminado
- Taipei Veterans General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Otros nombres:
|
|
Experimental: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Otros nombres:
|
|
Comparador activo: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Otros nombres:
|
|
Experimental: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Otros nombres:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Experimental: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Experimental: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
|
|
Experimental: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Otros nombres:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Otros nombres:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Periodo de tiempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Periodo de tiempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Periodo de tiempo: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Periodo de tiempo: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Periodo de tiempo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Periodo de tiempo: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Periodo de tiempo: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Periodo de tiempo: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Periodo de tiempo: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Periodo de tiempo: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Periodo de tiempo: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Periodo de tiempo: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Periodo de tiempo: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Clinical Lead, Inhibrx Biosciences, Inc
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Cáncer de cabeza y cuello
- Cáncer de pulmón
- NSCLC
- Cáncer de pulmón de células no pequeñas
- Carcinoma
- Neoplasias
- Inmunoterapia
- Pembrolizumab
- Quimioterapia
- Keytruda
- HNSCC
- Neoadyuvante
- Agentes antineoplásicos
- Auxiliar
- Tumores sólidos
- Cáncer oral
- Cáncer orofaríngeo
- INBRX-106
- Agentes antineoplásicos inmunológicos
- Neoplasias de Cabeza y Cuello
- Neoplasias Glandulares y Epiteliales
- Neoplasias por tipo histológico
- Neoplasias por sitio
- Carcinoma de células escamosas de cabeza y cuello
- Mecanismos moleculares de acción farmacológica
- PD-L1 positivo
- Neoplasias De Células Escamosas
- Carcinoma De Células Escamosas
- Cáncer de hipofaringe
- Fase 1 y Fase 2
- Ensayo clínico de fase 1 y fase 2
- Agonista del receptor OX40
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades de la Boca
- Enfermedades Estomatognáticas
- Neoplasias urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades de las vías respiratorias
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Enfermedades pulmonares
- Adenocarcinoma
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades de la piel
- Neoplasias Urológicas
- Enfermedades Otorrinolaringológicas
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Neoplasias Renales
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Tumores neuroendocrinos
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Enfermedades faríngeas
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Carcinoma de células escamosas de cabeza y cuello
- Neoplasias
- Neoplasias de Estómago
- Carcinoma
- Neoplasias Pulmonares
- Carcinoma De Células Escamosas
- Carcinoma De Célula Renal
- Carcinoma de pulmón de células no pequeñas
- Neoplasias de Cabeza y Cuello
- Melanoma
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias De Células Escamosas
- Neoplasias de la Boca
- Carcinoma De Células De Transición
- Neoplasias orofaríngeas
- Neoplasias por sitio
- Neoplasias Hipofaríngeas
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Químicos inorgánicos
- Compuestos de cloro
- Compuestos de nitrógeno
- Guanina
- Hipoxantino
- Purinones
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Taxaides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Economía y organizaciones de la atención médica
- Compuestos de platino
- Ciencias económicas
- Pemetrexed
- Gemcitabina
- Paclitaxel
- Cisplatino
- pembrolizumab
- Impuestos
Otros números de identificación del estudio
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Otro identificador: Merck Sharp & Dohme LLC)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .